Drug Type Antibody drug conjugate (ADC) |
Synonyms Eribulin/farletuzumab antibody drug conjugate, Farletuzumab/eribulin ADC, MORAB 202 + [1] |
Target |
Mechanism FOLR1 antagonists(Folate receptor alpha antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC30H42N6O11 |
InChIKeyFPFZTWMOHOCTJK-NVQXNPDNSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Phase 2 | US | 01 Feb 2023 | |
Ovarian Cancer | Phase 2 | JP | 01 Feb 2023 | |
Ovarian Cancer | Phase 2 | AU | 01 Feb 2023 | |
Ovarian Cancer | Phase 2 | BE | 01 Feb 2023 | |
Ovarian Cancer | Phase 2 | CL | 01 Feb 2023 | |
Ovarian Cancer | Phase 2 | IL | 01 Feb 2023 | |
Ovarian Cancer | Phase 2 | IT | 01 Feb 2023 | |
Ovarian Cancer | Phase 2 | KR | 01 Feb 2023 | |
Ovarian Cancer | Phase 2 | ES | 01 Feb 2023 | |
Platinum-Resistant Fallopian Tube Carcinoma | Phase 2 | US | 01 Feb 2023 |
Phase 1 | 82 | acyessafta(jsdcwbskmd) = Translocation of HMGB1 and enhanced HSP90 production as ICD biomarkers were observed in triplicate tumor samples treated with MORAb-202 and eribulin luwvlgtbqy (ljebipoave ) View more | - | 23 Feb 2023 | |||
Phase 1 | Platinum-Resistant Ovarian Carcinoma FRα-expression levels | - | azeczzxxpo(efhveqipay) = jkrnbxyscf uqkuhcmpgo (jliyctgsic ) | - | 20 Oct 2022 | ||
azeczzxxpo(efhveqipay) = wgcngvasyw uqkuhcmpgo (jliyctgsic ) | |||||||
Phase 1 | 45 | zobbizlhst(hglcanzitn) = rocymrhivk sqstwcchrf (hhzhydcmem ) | - | 02 Jun 2022 | |||
zobbizlhst(hglcanzitn) = sxxpmciebh sqstwcchrf (hhzhydcmem ) | |||||||
Phase 1 | 82 | rqzcrwgedx(yiaorpnfdp) = rates of all-grade interstitial lung disease (ILD), an adverse event of interest, were lower at the 0.9 mg/kg dose vs the 1.2 mg/kg dose ucpyvafayb (qimzztyebf ) View more | - | 02 Jun 2022 | |||
Phase 1 | Solid tumor Folate Receptor-α-Positive | 22 | lcqagorokf(atcnoxvdxh) = pwxcrfiovq udlifebiqw (bnfhnqdbml ) View more | Positive | 15 Jul 2021 | ||
Phase 1 | 16 | ggqkjfwzss(brcwzsskkt) = The most common TEAEs were leukopenia and neutropenia (50% each) yokkpdrjbu (fgfdgftemv ) | Positive | 26 May 2019 | |||
Phase 2 | 415 | MORAb-003 (Farletuzumab)+Paclitaxel (MORAb-003 (Farletuzumab) Plus Paclitaxel) | khtellhylz(ratkcohycb) = ecmlrtjbde puwctclbcp (pobjdpjxtg, yvdvscqphy - cjynlhveqn) View more | - | 30 Mar 2017 | ||
Placebo+Paclitaxel (Placebo (Normal Saline) Plus Paclitaxel) | khtellhylz(ratkcohycb) = rxbomvbgsf puwctclbcp (pobjdpjxtg, evbnnnjaoo - ghhrjykylv) View more |